月旦知識庫
 
  1. 熱門:
 
首頁 臺灣期刊   法律   公行政治   醫事相關   財經   社會學   教育   其他 大陸期刊   核心   重要期刊 DOI文章
中醫藥雜誌 本站僅提供期刊文獻檢索。
  【月旦知識庫】是否收錄該篇全文,敬請【登入】查詢為準。
最新【購點活動】


篇名
血竭及其成分的活血化瘀活性研究
並列篇名
Studies on the Vasoactive-Antithrombotic Effect of Draconis Resina and Its Components
作者 蔡維人謝慧姿陳建志 (Jiann-Jy Chen)陳介甫
中文摘要
血竭(Draconis Resina)為棕櫚科(Palmae)植物麒麟竭果實及樹幹滲出的睛紅色樹脂,記載中具有活血化瘀及止血功效。由活體動物(in Vivo)實驗結果穎示:(1)血渴以腹腔給藥對鼯鼠的一半致死劑量及其95%可信限分別為3.98及3.53~4.48g/kg。(2)血竭以腹腔給藥(0.6~3.0k/kg),是可以縮短ICR鼯鼠的出血時間。(3)血竭以腹腔給藥(1.0和1.5g/kg),可以有意義地減少醋酸誘導鼯鼠腹部產生的抽搐作用,但對熱引致鼯鼠的疼痛並沒有抑制作用(1.5和2.5g/kg)。另外,由離體(in vitro)實驗結果顯示:(1)血竭在兔子血小板懸浮液中,能夠抑制花生四烯酸、膠原蛋白或血小板活化因子所引起的凝集,其IC50分別為11.0、11.0和37.0μg/ml;但血竭在25.0μg/ml時,反而會促進凝血酵素引起的血小板凝集作用。血竭的存在對血漿凝因時間並無影響。(2)血竭成分之(2S)-5-甲氧基-6-甲基黃烷-7-醇((2S)-5-methoxy-6-methylnavan-7-ol)在血小板懸浮液中,對花生四烯酸、膠原蛋白、血小板活化因子、U46619或ADP所引發之凝集具抑制作用,且呈現劑量-效應對應關係,其IC50分別為12.5、4.3、47.3、27.4、45.0μg/kg。但(2S)-5-methoxy-6-methslnavan-7-ol對血漿凝固時間及纖維溶解並無影響。(3)血竭成分之血竭紅素(dracorubin)與去甲法血竭紅素(nordracorubin)可以促進血小板凝集作用,但對血漿凝因時間並無影響。綜合上述結果,血竭是具活血化瘀之效,亦有部份止痛之效。其活性成分之(2S)-5-methoxy-6-methylflavan-7-ol具抗血小板活性,但dracorubin與nordracorubin卻具促進血小板活化之效。其成分在活血化瘀之作用機轉仍在進一步探討。
英文摘要
Draconis Resina, a red resin secreted from the fruits of Daemonorops draco Blume, has been used as a vasoactive-antithrombotic agent for treat thrombotic stroke and as a hemostatic agent by Chinese physicians. In vivo studies yielded the following results: (1) The median lethal dose and 95% confidence limits of Draconis Resina by intraperitoneal injection to ICR mice were 3.98 and 3.53-4.48g/kg, respectively; (2) Draconis Resina (0.6-3.0 g/kg, i. p.) shortened the tail bleeding time in conscious mice; (3) Draconis Resina (1.0 and 1.5 g/kg, i. p.) significantly decreased the writhing response induced by acetic acid in mice. However, Draconis Resina (1.5 and 2.5 g/kg, i. p.) had no analgesic effect as evaluated by the hot-plate method. On the other hand, in vitro studies indicated that (1) Draconis Resina inhibited the aggregation of washed rabbit platelets induced by arachidonic acid (AA), collagen and platelet-activating factor (PAF) (IC50: 11.0, 11.0 and 37.0μg/ml, respectively) and enhanced thrombin-induced aggregation even though Draconis Resina had no effect on coagulation as evaluated by the prothrombin time (PT) and activated partial thromboplastin time (APTT); (2) (2S)-5-methoxy-6-methylflavan-7-ol, one of the bioactive components in Draconis Resina, dose-dependently inhibited rabbit platelet aggregation induced by AA, collagen, PAF, U46619 or ADP (IC50: 12.5, 4.3, 47.3, 27.4, and 45.0μg/ml, respectively) in platelet suspension although (2S)-5-methoxy-6-methylflavan-7-ol had no effect on the PT and APTT, the fibrinolytic system; (3) Dracorubin and nordracorubin, other bioactive principles in Draconis Resina, enhanced platelet aggregation but did not affect PT and APTT. The present studies demonstrated that Draconis Resina possessed vasoactive-antithrombotic activity and some analgesic effect. The activities of Draconis Resina components include the antiplatelet activity by (2S)-5-methoxy-6-methylflavan-7-ol and enhancement of platelet activation by dracorubin and nordracorubin. Further studies are needed to elucidate the action mechanism of Draconis Resina and its components.
起訖頁 59-73
關鍵詞 血竭活血化瘀血小板2S-5-甲氧基-6-甲基黃烷-7-醇血竭紅素去甲基血竭紅素Draconis ResinaVasoactive-antithromboticPlatelets2S-5-methoxy-6-methylflavan-7-olDracorubinNordracorubin
刊名 中醫藥雜誌  
期數 199503 (6:1期)
出版單位 衛生福利部國家中醫藥研究所(原:國立中國醫藥研究所)
該期刊-上一篇 保健植物之生產促進與白鶴靈芝之加工研究
 

新書閱讀



最新影音


優惠活動




讀者服務專線:+886-2-23756688 傳真:+886-2-23318496
地址:臺北市館前路28 號 7 樓 客服信箱
Copyright © 元照出版 All rights reserved. 版權所有,禁止轉貼節錄